SECIntel
Float & OS— / 171.61 M
Cash/Shr$0.63
Market Cap & EV—
Short Interest—
Cash$107.86 M
Est. Cash Today$80.70 M
Off Ability—
Off Freq—
Dilution—
Cash Need—
Overall Offering Risk—
Warrant Exercise Risk—
Nasdaq Compliance—

Shares Outstanding History

Cash Position

Cash Position

The company has 8.8 months of cash left based on the quarterly cash burn of $-27.56 M and estimated current cash of $80.70 M.

Commentary on Financial Condition

“As of March 31, 2026, we had $125.7 million of cash, cash equivalents and marketable securities. We have incurred net operating losses since inception. As of March 31, 2026, our accumulated deficit was $654.4 million. To date, we have funded operations through issuances and sales of equity securities and debt, in addition to revenue generated from our drug creation agreements. We believe that our cash, cash equivalents and marketable securities will be sufficient to meet our operating expenses, working capital and capital expenditure needs over at least the next 12 months following the date of this filing.” (from May 2026 filing’s Liquidity and Capital Resources) Filed At: 2026-05-07

Recent Filings
4Form 42026-09-01
10-QForm 10-Q2026-08-11
8-KForm 8-K2026-08-11
4Form 42026-08-07
3Form 32026-08-07
4Form 42026-07-06
4Form 42026-06-26
8-KForm 8-K2026-06-24
Insights
The company completed 1 offering(s) in the last twelve months, raising $93,500,000.
· 2026-06-24
An at-the-market programme of up to $100,000,000 is in place.
10-Q · 2026-05-07
A shelf registration of $400,000,000 is on file, of which $93,500,000 has been taken down, leaving $306,500,000 available.
S-3 · 2025-08-25
An at-the-market programme of up to $100,000,000 is in place.
424B5 · 2023-06-16